Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

Boehringer Ingelheim

Status: Begins enrollment this month

Conditions: Generalized Pustular Psoriasis

Treatments: Drug: Spevigo®

Study type: Observational

Funder types: Industry

Identifiers

NCT06886009

1368-0122

Details and patient eligibility

About

The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.

Enrollment: 21 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients starting Spesolimab IV for the first time in accordance with the approved label in Korea (complete enumeration for the first 2 years after product launch)
• Patients with generalized pustular psoriasis (GPP) flare
• Age >/=19 years at enrolment
• Patients who have signed the data release consent form

Exclusion criteria

• Patients with Severe or life-threatening hypersensitivity to Spesolimab or to any of the excipients
• Patients with clinically important active infections (e.g. active tuberculosis)

Trial design

21 participants in 1 patient group

Patients with flares with generalized pustular psoriasis (GPP)

Treatment:

Drug: Spevigo®